Authors
Latest:
Targeting the Affluent: Differential Access to Targeted Therapies in ChinaDisparities in income levels in China continue to drive far-reaching differences in how poorer and richer cancer patients are treated, with recent data suggesting that the differences in access to treatment lead to different outcomes for poorer patients. Peter De Richter reports.
Latest:
The Fundamental Pillars of Good ForecastingMaiko Midena discusses the key fundamentals to success when it comes to forecasting with large multinational pharmaceutical organizations.
Latest:
Leveraging Health IT to Improve Drug DevelopmentThe FDA's Mary Ann Slack outlines how the Agency is working to adopt electronic practices by initiating efforts to simplify the submission process for new drug and generic drug applications.
Latest:
Global Harmonization of Customer DataCherry Cabading and Mona Rakibe outline how the use of modern data management techniques can help companies see improvements in sales effectiveness, data steward productivity and overall data quality.
Latest:
Syncing Social Media With Value-Care ModelOutlining the new communication priorities necessary to excel in the emerging outcomes-based healthcare landscape.
Latest:
Why Pharma Needs to Catch Up On DigitalA recent IT leadership survey found that many more pharma companies are reporting their digital strategies are ineffective compared to other industries. Heath Jackson looks at why this is – and what they need to do about it.
Latest:
mAb Biosimilars: The Future of Cancer Treatment?Time will determine the shape of biosimilar usage in oncology, but they will play a significant role in the battle against cancer in the future, writes Alessandra Franceschetti.
Latest:
Beyond the Science: Commercial Implications From ASCO 2017Four strategic takeaways from this year's that are important for pharma oncology leaders.
Latest:
The Future of Real-World StudiesPharma companies today must increasingly provide evidence on real-world outcomes to differentiate and justify their products. But what is the true potential of real-world evidence studies and what are the right questions to ask in determining product performance in the marketplace?
Latest:
How Emerging Biopharmas Can Obtain VC FundingKen Shimokawa, Founder and General Partner of G4S Capital, shares insights into what venture capitalists look for when evaluating emerging biopharmaceutical opportunities.
Latest:
Aligning Early Advice with Long-Term PlanningThe five ways pharma developers can get the most out of early engagement with payers and regulators when plotting their clinical and commercial evidence plans.
Latest:
Time to Disrupt SOPsPharma companies still keep thousands of manufacturing procedures as text documents, an inefficient method can lead to defective batches, recalls and warning letters. Why not use video for training where applicable, asks Boaz Sigelman.
Latest:
Packaging for Patient EngagementFunso Olufade discusses how solutions such as the new Adherence Package can help increase pharma–patient engagement.
Latest:
Financial Toxicity: Tracking a Growing Side EffectJeremy Schafer and Deborah Lotterman discuss the impact that financial toxicity is having on patients and payers and outline the strategies pharma need to adopt to begin to remedy it.
Latest:
Functional Service Partnerships: A Case Study for CRO Resource ManagementA review of a recent FSP in which the CRO partner assumed clinical monitoring and site support responsibility for more than 50 ongoing trials.
Latest:
Functional Service Partnerships: A Case Study for CRO Resource ManagementA review of a recent FSP in which the CRO partner assumed clinical monitoring and site support responsibility for more than 50 ongoing trials.
Latest:
Functional Service Partnerships: A Case Study for CRO Resource ManagementA review of a recent FSP in which the CRO partner assumed clinical monitoring and site support responsibility for more than 50 ongoing trials.
Latest:
Key Regulatory Deadlines Loom for Drug Dispensers and WholesalersThe COVID-19 pandemic is currently top of mind among pharma professionals, but stakeholders have other business to attend to – such as the upcoming deadline to meet regulatory requirements of the US FDA’s 2013 Drug Supply Chain Security Act.
Latest:
AI & Lab Data: Enabling Decision-Making in Real TimeLisa Kerber outlines how the pharma industry can take advantage of combining new clinical data sources such as diagnostics, or lab data, with AI to deliver on the promise of improving outcomes.
Latest:
Can A New Value Framework Help Ease Friction Over Orphan Drug Prices?Even on the contentious topic of orphan drug pricing, the last few months have brought hopeful signs that patients, pharmaceutical companies, health insurers, and the academic bodies that counsel them are trying to speak the same language.
Latest:
mHealth: Changing the Dynamics of the Healthcare EcosystemmHealth devices and apps that continuously monitor patient symptoms and help with adherence also are likely to reshape medical practice – and with it the products pharma produce, writes Vicki Anastasi.
